What question did this study set out to answer?

To develop an oxygen-unrestricted synergistic nanosystem combining a Type I/II photosensitizer and a hypoxia-activated prodrug to treat both normoxic and hypoxic tumor regions.

August 20, 2026Small

Combining Type I&II Photosensitizer With Hypoxia‐Activated Prodrug Enables Oxygen‐Unrestricted Synergistic Photocatalytic Therapy

View Full Paper

Ask AI

Bookmark

Authors

HHHaoran HouShandong University HLHanhan LuDalian University of Technology YWYingnan WuNational University of Singapore

Discussion

Member takes

Implication

Preclinical study demonstrates enhanced antitumor efficacy of a dual-action photosensitizer and hypoxia-activated prodrug nanoparticle, suggesting a viable oxygen-unrestricted cancer therapy.

Key Points

To develop an oxygen-unrestricted synergistic nanosystem combining a Type I/II photosensitizer and a hypoxia-activated prodrug to treat both normoxic and hypoxic tumor regions.
Engineered a mitochondria-targeting nanoparticle (DT@TH302) co-encapsulating the dual Type I/II photosensitizer DT and the hypoxia-activated prodrug TH-302.
Evaluated light-induced reactive oxygen species generation, NAD+/NADH redox disruption, hypoxia induction, DNA cross-linking, and immunogenic cell death in vitro and in vivo.
Light activation of DT@TH302 generated high levels of singlet oxygen and superoxide anions, disrupting NAD+/NADH redox balance and causing mitochondrial dysfunction.
Oxygen depletion from photodynamic therapy exacerbated local hypoxia, triggering TH-302-mediated DNA cross-linking and apoptosis while DT maintained Type I photocatalysis under hypoxia.
Nanoparticles showed tumor-targeting ability, biosafety, immunogenic cell death stimulation, and significant tumor growth inhibition in vivo.

Cite This Study

Hou et al. (2026) studied this question.

synapsesocial.com/papers/6a86b5ff8a91293e6a1cdb1b https://doi.org/10.1002/smll.75270

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates enhanced antitumor efficacy of a dual-action photosensitizer and hypoxia-activated prodrug nanoparticle, suggesting a viable oxygen-unrestricted cancer therapy.

Combining Type I&II Photosensitizer With Hypoxia‐Activated Prodrug Enables Oxygen‐Unrestricted Synergistic Photocatalytic Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Combining Type I&II Photosensitizer With Hypoxia‐Activated Prodrug Enables Oxygen‐Unrestricted Synergistic Photocatalytic Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider